# Pizarra — PT-pseudo_c7277954c60f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c7277954c60f
Task: 1

Encounter: Urology - outpatient on 18 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 9.8 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.073 ng/mL²
  - PSA velocity: 1.0 ng/mL/yr
  - Prior PSA: 8.6 ng/mL
  - Prostate volume: 134.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5260261 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30)
  - Problem list / PMHx: Obesity (BMI >30)
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 9.8 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 134 mL. csPCa 0.53.

Vitals: weight 74 kg, height 176 cm, BMI 23.9, BP 125/82 mmHg, HR 86 bpm. Smoking: Ex-smoker (12 pack-yr, quit 2017).

Chief complaint: Specialist evaluation requested to interpret recent multiparametric imaging results and address a steadily ascending PSA trajectory.

History: At 54 years of age, this retired shopkeeper shares a household with his unmarried partner and seeks re-evaluation for a persistently rising PSA curve. Lower urinary tract complaints are minimal, requiring no drug therapy. Physical activity includes biweekly home weight training, while alcohol consumption remains limited to one unit weekly. Tobacco cessation occurred in 2017 after a 12 pack-year exposure. Vision has progressively worsened over recent years, mandating large-print formats for all clinical documentation. Medical history includes obesity (BMI >30), stable COPD requiring periodic pulmonary function testing, and a recently completed endocrine assessment for thyroid screening. He explicitly denies bone discomfort, haematuria, or unexplained weight loss, maintaining overall stability throughout the diagnostic phase.

Physical examination: Genital assessment unremarkable; per rectum, digital rectal examination confirms a normal DRE. The gland appears symmetrically enlarged with a smooth, rubbery texture, devoid of palpable nodules or asymmetry. Systemic evaluation shows stable vital signs, absent lymphadenopathy, and no indicators of broader illness.

Patient info: retired shopkeeper; Living with partner (unmarried); Lives with partner.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 1 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.45 +/- 0.24   (95% CI 0.05-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.23  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 1.9 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=2.0, bx_ord=0.0, psa=9.8, age=54.0, psad=0.073, dre_ord=0.0, vol=134.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: DEFER BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=2, PSA=9.8, csPCa probability=0.53) and failed to incorporate the context of the rising PSA velocity (1.0 ng/mL/yr) and the specific PSA density (0.073 ng/mL²). It also did not weigh the clinical context of the normal DRE and the patient's history of obesity and COPD.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested "NO BIOPSY" with a wide uncertainty interval (0.45 +/- 0.24). This wide interval suggests the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. Furthermore, the prior ignores the guideline criterion that mandates biopsy for PI-RADS $\ge 3$ lesions, which is the primary factor the prior failed to weigh.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology notes
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, and the track record shows that applying a PSA-D cut-off of $0.15 \text{ ng/mL/cc}$ can avoid biopsies while missing some cancer.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_c7277954c60f", "radiology_report": "Subject: Multiparametric MRI Prostate | Facility: Amsterdam UMC, AMC | Date: 15 Feb 2025\n\nClinical indication: Elevated PSA at 9.8 ng/mL, obtained for routine surveillance imaging.\n\nFINDINGS:\nThe gland exhibits marked hypertrophy, spanning roughly 5.8 x 5.2 x 4.6 cm and culminating in a total volume of 134.0 mL. Transition zone changes feature extensive benign nodular hyperplasia; the enlarged median lobe presses gently against the bladder base. Peripheral zone architecture remains uniform with standard T2 signal characteristics and absent restricted diffusion. Scanning reveals no focal abnormality warranting a PI-RADS 3 or greater classification.\n\nIMPRESSION:\nProstatic hypertrophy (total volume 134.0 mL) lacking a PI-RADS 3+ focus.\nPI-RADS 2.\nPSA density: 0.073.\ncsPCa probability 0.5260261."}
get_psa_trend
{"case_id": "PT-pseudo_c7277954c60f", "psa_trend": [{"date": "Jan 2024", "val": 1.1}, {"date": "May 2024", "val": 2.9}, {"date": "Aug 2024", "val": 6.0}, {"date": "Nov 2024", "val": 3.8}, {"date": "Feb 2025", "val": 9.8}]}
get_previous_notes
{"case_id": "PT-pseudo_c7277954c60f", "previous_notes": [{"date": "28 Aug 2023", "author": "Dr. E. Mulder (GP)", "text": "28 Aug 2023 consultation noted mild urinary hesitancy with minimal patient concern. Initial serum PSA measured 6.1 ng/mL. Subsequent testing in early 2024 demonstrated a progressive upward trend, leading to this current urological referral for comprehensive assessment."}]}
get_lab_results
{"case_id": "PT-pseudo_c7277954c60f", "laboratory_results": [{"name": "PSA", "val": "9.8 ng/mL", "date": "27 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.97 ng/mL", "date": "27 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "20%", "date": "27 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "16.5 g/dL", "date": "27 Jan 2025", "flag": ""}, {"name": "WBC", "val": "6.7 x10^9/L", "date": "27 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "324 x10^9/L", "date": "27 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "78 umol/L", "date": "27 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "27 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.1 nmol/L", "date": "27 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "50 U/L", "date": "27 Jan 2025", "flag": ""}, {"name": "LDH", "val": "184 U/L", "date": "27 Jan 2025", "flag": ""}]}
NOT RETRIEVED
The specific ISUP grade or Gleason score of any prior biopsy is not documented, which is needed to assess the characterization problem.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity of 1.0 ng/mL/yr, indicating a steadily ascending trajectory.
- PSA has risen from 6.1 ng/mL (Aug 2023) to 9.8 ng/mL (Feb 2025).

AGAINST sampling this patient now:
- mpMRI report: PI-RADS score of 2, which falls into the category where biopsy is deferred.
- mpMRI report: "no focal abnormality warranting a PI-RADS 3 or greater classification."

WHERE THIS LEANS
The evidence points towards deferring biopsy based on the current imaging findings (PI-RADS 2), despite the concerning PSA velocity. This contradicts the statistical prior's suggestion of "NO BIOPSY" but aligns with the guideline criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the mpMRI report explicitly assigned a PI-RADS score of 2, which falls below the threshold for biopsy according to the guideline criterion. This finding was decisive, overriding the statistical prior's suggestion. Although the PSA velocity was concerning (1.0 ng/mL/yr), the lack of a PI-RADS 3+ focus in the retrieved radiology report dictates a deferral. The evidence converges on avoiding unnecessary sampling based on imaging findings.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
